Sean P. Pitroda & Ralph R. Weichselbaum provide a Commentary on Iowis Zhu et al.: https://doi.org/10.1172/JCI195652
Address correspondence to: Ralph Weichselbaum, Department of Radiation and Cellular Oncology, The University of Chicago, 5,758 S. Maryland Ave., Chicago, Illinois 60,637, USA.
Find articles by Pitroda, S. in: | Google Scholar
Department of radiation and cellular oncology, the university of chicago, chicago, illinois, USA.
With Dr. Tomasz (Tom) Beer MD – Chief Medical Officer for MCED at Exact Sciences
From precision oncology pioneer to leading the shift toward population-scale early detection via blood-based tech. The future of cancer care: intercepting it before it’s too late.
Dr. Tomasz Beer, MD is a nationally recognized medical oncologist and clinical research leader who serves as Chief Medical Officer for Multi-Cancer Early Detection at @ExactSciences Corporation (https://www.exactsciences.com/), a molecular diagnostics company focused on the eradication of cancer by preventing it, detecting it earlier, and guiding personalized treatment.
Before joining Exact Sciences, Dr. Beer spent decades at the forefront of academic oncology, including serving as Deputy Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he helped build one of the country’s leading precision cancer programs.
A prostate cancer specialist by training, Dr. Beer has led numerous clinical trials, authored hundreds of peer-reviewed publications, and been a driving force in advancing biomarker-guided cancer therapy. His career has spanned the evolution of oncology—from empiric chemotherapy to precision medicine and now toward population-scale cancer detection.
The TOI Tech Desk is a dedicated team of journalists committed to delivering the latest and most relevant news from the world of technology to readers of The Times of India. TOI Tech Desk’s news coverage spans a wide spectrum across gadget launches, gadget reviews, trends, in-depth analysis, exclusive reports and breaking stories that impact technology and the digital universe. Be it how-tos or the latest happenings in AI, cybersecurity, personal gadgets, platforms like WhatsApp, Instagram, Facebook and more; TOI Tech Desk brings the news with accuracy and authenticity.
Researchers at the Johns Hopkins Kimmel Cancer Center have discovered how certain pathogenic bacteria in gut and breast tissue can promote breast cancer development and progression by hijacking a key metabolic enzyme known as spermine oxidase (SMOX). In a study led by Dipali Sharma, Ph.D., professor of oncology, investigators found that exposure to pathogenic bacteria such as Bacteroides fragilis, Fusobacterium nucleatum, and Escherichia coli significantly increased SMOX activity, leading to DNA damage, tumor growth, and metastasis in laboratory and animal models of breast cancer.
The work, published in Cancer Research, reveals a novel link between microbial dysbiosis—the imbalance of good and harmful bacteria—and breast cancer, and identifies SMOX as a potential therapeutic target.
“Microbes don’t just reside in our gut. They can directly influence cancer behavior,” says Sharma. “We found that an overabundance of certain pathogenic bacteria triggers inflammation and activates SMOX, producing reactive oxygen species that damage DNA and fuel tumor growth. By blocking SMOX, we were able to dramatically reduce tumor formation in our preclinical models.”
University scientists team up with IBM to engineer the new molecule atom-by-atom in quantum-centric study.
In this systematic review and network meta-analysis, diclofenac and silymarin were the most effective preventive strategies for hand-foot syndrome in patients with cancer, with silymarin requiring confirmation in a larger randomized trial.
Diclofenac emerged as the agent with the best overall supporting evidence, informed by both effect estimates and study quality.
Question Which of the prophylactic agents for treating chemotherapy-induced hand-foot syndrome (HFS) is the most effective for preventing clinically significant HFS in patients with cancer?
Findings In this systematic review and network meta-analysis of 17 randomized clinical trials including 2,192 patients, topical diclofenac, silymarin, 400-mg pyridoxine, and celecoxib significantly reduced the incidence of grade 2 or higher HFS compared with placebo; diclofenac and celecoxib were also effective in reducing overall HFS incidence.
Meaning These findings indicate that diclofenac is the prophylactic agent with the best supporting evidence for prevention of HFS in patients with cancer.
In patients with hemorrhagic cerebral small vessel disease, left ventricular mass is associated with MRI markers of arteriolosclerosis. @UCLStrokeRes
BackgroundMost intracerebral hemorrhages (ICH) are caused by 1 of 2 cerebral small vessel diseases (cSVDs): arteriolosclerosis and cerebral amyloid angiopathy (CAA). Hypertension is a major risk factor for ICH, but its contribution to the hemorrhagic manifestations of these arteriopathies remains uncertain. We investigated associations between a cardiac structural biomarker of systemic hypertension (left ventricular mass [LVM]) and cSVD neuroimaging phenotype in patients with ICH.
Satapathy et al. demonstrate that prostaglandin E2 promotes YAP-dependent nuclear translocation of PD-L1 via importin-α3. In the nucleus, PD-L1 cooperates with YAP-TEAD to enhance transcriptional activity, revealing a noncanonical role for PD-L1 in regulating oncogenic gene expression beyond immune evasion.